Betamethasone

證據等級: L5

預測適應症: 5 個

Betamethasone: From Inflammatory Conditions to Erythema Multiforme

One-Sentence Summary

Betamethasone is a potent synthetic glucocorticoid widely used for various inflammatory, allergic, and autoimmune conditions across 97 registered products in Malaysia. The TxGNN model predicts it may be effective for Erythema Multiforme (EM), with 17 clinical trials and 20 publications currently providing supporting or related evidence for this direction.

Quick Overview

Item	Content
Original Indication	Anti-inflammatory / immunosuppressive corticosteroid (broad dermatological, rheumatic, and allergic indications)
Predicted New Indication	Erythema Multiforme
TxGNN Prediction Score	0.00% (rank 1)
Evidence Level	L3 — Observational studies and case series available
Malaysia Market Status	✓ Marketed
Number of Registrations	97
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Erythema multiforme (EM) is an acute, immune-mediated hypersensitivity reaction affecting the skin and mucous membranes, primarily driven by CD8+ cytotoxic T-cell attack on keratinocytes. The condition exists on a clinical spectrum that includes mild cutaneous EM minor at one end and the severe, life-threatening Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) at the other. The underlying immunopathology — T-cell activation, pro-inflammatory cytokine release, and keratinocyte apoptosis — is well-characterized.

Betamethasone, as a high-potency synthetic glucocorticoid, exerts its effects by suppressing T-cell activation, inhibiting the release of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), and reducing keratinocyte apoptotic signalling. These mechanisms directly oppose the key pathological processes driving EM. In severe EM variants (SJS/TEN), topical betamethasone has already been reported in clinical use, particularly for ocular complications (PMID 37182731), lending real-world support to this mechanistic rationale.

However, a critical caveat exists: EM itself has been reported as an adverse reaction to betamethasone treatment (PMID 14206262), suggesting a paradoxical relationship. This bidirectional association — where the drug may both treat and occasionally trigger the condition — necessitates careful patient selection and monitoring. The mechanistic link is rated as moderate-to-strong, but the paradoxical induction risk must be factored into any clinical translation.

Clinical Trial Evidence

Note: No clinical trials directly studying betamethasone for erythema multiforme were identified. The trials below involve betamethasone or related potent corticosteroids in dermatological or EM-spectrum conditions (SJS/TEN), providing indirect supportive evidence.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03331523	Phase 3	Completed	643	Generic calcipotriene/betamethasone dipropionate topical suspension vs Taclonex® for scalp psoriasis. Demonstrates large-scale safety of topical betamethasone in inflammatory skin disease.
NCT03731091	Phase 3	Completed	494	Generic calcipotriene/betamethasone dipropionate foam vs Enstilar® for plaque psoriasis. Confirms topical betamethasone efficacy and tolerability.
NCT01422434	Phase 3	Completed	676	LEO 90105 ointment (calcipotriol + betamethasone dipropionate) vs monotherapy in Japanese psoriasis vulgaris patients. Large-scale safety data in Asian population.
NCT02319616	Phase 1/2	Withdrawn	0	Clobetasol 0.05% ointment for TEN — directly on the EM/SJS/TEN spectrum. Unfortunately withdrawn with no data generated.
NCT05185258	Phase 4	Active, not recruiting	12	Enstilar® (calcipotriol/betamethasone) and NB-UVB therapy investigating residual disease memory in psoriatic skin. Explores corticosteroid effects on immune memory.
NCT00820950	Phase 2	Completed	29	Ruxolitinib phosphate cream dose-escalation study in plaque psoriasis. Provides comparative context for topical anti-inflammatory agents.
NCT03880357	Phase 1	Completed	485	Bioequivalence study of betamethasone-containing product for scalp psoriasis. Large-scale tolerability data.
NCT03395132	Phase 3	Terminated	68	Fusidic acid/betamethasone cream (Fucicort®) in clinically infected atopic dermatitis/eczema. Terminated early but relevant to infected inflammatory skin conditions.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37182731	2023	Clinical Study / Case Series	Am J Ophthalmol	Topical betamethasone treatment of SJS/TEN with ocular involvement in the acute phase. Demonstrates direct clinical use of betamethasone in the EM-spectrum.
40500649	2025	Review	Allergol Int	Updates on ocular manifestations and treatment of SJS/TEN. Confirms importance of early topical steroid intervention for ocular complications.
38795750	2024	Cohort / National Study	Am J Ophthalmol	National survey in Japan on SJS/TEN ocular sequelae incidence and prognostic factors (2016–2018 vs 2005–2007). Evidence of improving prognosis with treatment advances.
14206262	1964	Case Report (Adverse Event)	Br J Clin Pract	Critical safety signal: EM occurring during betamethasone treatment for pruritus vulvae and neurodermatitis. Documents paradoxical EM induction.
1068978	1976	Review	Int Dent J	Corticosteroids in oral mucosal diseases, including betamethasone valerate 0.1 mg for oral EM. Reports efficacy when administered during prodromal phase.
26297574	2015	Protocol	Trials	RCT protocol for topical clobetasol in TEN treatment. Supports rationale for potent topical corticosteroids in the EM-SJS-TEN spectrum.
2011350	1991	Open Trial	Oral Surg Oral Med Oral Pathol	Clobetasol propionate in adhesive paste for chronic oral vesiculoerosive diseases, including EM patients. 4 chronic EM patients showed improvement.
32105227	2020	Case Report	Gen Dent	Fluconazole-induced EM in immunocompetent patient. Provides pathophysiology context and treatment approach for drug-induced EM.
37854261	2023	Case Report	Clin Case Rep	EM provoked by radiotherapy in a 63-year-old patient. Disseminated erythematous lesions treated with corticosteroid-based approach.
22082897	2011	Case Report	Intern Med (Tokyo)	Severe obliterative bronchitis associated with SJS. Betamethasone was directly administered as primary treatment for SJS.

Malaysia Market Information

Betamethasone has 97 registered products and is actively marketed in Malaysia. Detailed license-level data (authorization numbers, product names, dosage forms, and approved indications) was not available in the current data extract. Below is a summary of known status:

Item	Content
Total Registrations	97
Market Status	Marketed
Common Dosage Forms	Topical cream/ointment, injection, oral tablet, eye drops (based on global betamethasone formulations)
Primary Approved Indications	Anti-inflammatory and immunosuppressive conditions (dermatological, rheumatic, allergic, and ophthalmic indications)

Safety Considerations

Detailed safety data (key warnings, contraindications, and drug interactions) was not available in the current data extract. Please refer to the package insert for comprehensive safety information.

Known class-level considerations for potent glucocorticoids:

Prolonged use may cause skin atrophy, striae, telangiectasia (topical), and adrenal suppression (systemic)
Immunosuppression increases infection risk
Paradoxical EM induction has been documented during betamethasone treatment (PMID 14206262) — requires vigilant monitoring
Systemic absorption from extensive topical application or occlusive dressings may cause hypothalamic-pituitary-adrenal (HPA) axis suppression

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between betamethasone’s immunosuppressive properties and EM’s immune-mediated pathology is moderate-to-strong. Literature evidence directly supports use of betamethasone in the SJS/TEN spectrum (severe EM variants), and corticosteroids are already used off-label for oral and ocular EM manifestations. However, the absence of EM-specific clinical trials and the documented paradoxical EM induction by betamethasone warrant a cautious approach.

To proceed, the following is needed:

Mechanism of action (MOA) data: Obtain detailed betamethasone MOA from DrugBank to strengthen mechanistic rationale
Package insert safety data: Download and parse the full prescribing information from NPRA for key warnings, contraindications, and drug interactions
Targeted literature review: Systematic review of corticosteroid use specifically in EM minor (non-SJS/TEN) to distinguish evidence from the broader EM-SJS-TEN spectrum
Paradoxical risk assessment: Formal evaluation of the incidence and risk factors for corticosteroid-induced EM, to develop patient exclusion criteria
Route-of-administration analysis: Determine which betamethasone formulations (topical, oral, injectable, ophthalmic) are most appropriate for different EM presentations
Prospective observational study design: Plan a pilot observational study or case registry for betamethasone in moderate-to-severe EM to generate direct clinical evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.